Kidney Transplantation After Rescue Allocation-the Eurotransplant Experience: A Retrospective Multicenter Outcome Analysis.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
01 06 2022
Historique:
pubmed: 6 10 2021
medline: 31 5 2022
entrez: 5 10 2021
Statut: ppublish

Résumé

At Eurotransplant (ET), kidneys are transferred to "rescue allocation" (RA), whenever the standard allocation (SA) algorithms Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP) fail. We analyzed the outcome of RA. Retrospective patient clinical and demographic characteristics association analyses were performed with graft outcomes for 2422 recipients of a deceased donor renal transplantation (DDRT) after RA versus 25 481 after SA from 71 centers across all ET countries from 2006 to 2018. Numbers of DDRTs after RA increased over the time, especially in Germany. RA played a minor role in ESP versus ETKAS (2.7% versus 10.4%). RA recipients and donors were older compared with SA recipients and donors, cold ischemia times were longer, waiting times were shorter, and the incidence of primary nonfunction was comparable. Among ETKAS recipients, HLA matching was more favorable in SA (mean 3.7 versus 2.5). In multivariate modeling, the incidence of graft loss in ETKAS recipients was reduced in RA compared with SA (subdistribution hazard ratio, 0.80; 95% confidence interval [0.70-0.91], P < 0.001), whereas other outcomes (mortality, death with functioning graft (DwFG)) were not significantly different. None of the 3 outcomes were significantly different when comparing RA with SA within the ESP program. Facing increased waiting times and mortality on dialysis due to donor shortage, this study reveals encouragingly positive DDRT outcomes following RA. This supports the extension of RA to more patients and as an alternative tool to enable transplantation in patients in countries with prohibitively long waiting times or at risk of deterioration.

Sections du résumé

BACKGROUND
At Eurotransplant (ET), kidneys are transferred to "rescue allocation" (RA), whenever the standard allocation (SA) algorithms Eurotransplant Kidney Allocation System (ETKAS) and Eurotransplant Senior Program (ESP) fail. We analyzed the outcome of RA.
METHODS
Retrospective patient clinical and demographic characteristics association analyses were performed with graft outcomes for 2422 recipients of a deceased donor renal transplantation (DDRT) after RA versus 25 481 after SA from 71 centers across all ET countries from 2006 to 2018.
RESULTS
Numbers of DDRTs after RA increased over the time, especially in Germany. RA played a minor role in ESP versus ETKAS (2.7% versus 10.4%). RA recipients and donors were older compared with SA recipients and donors, cold ischemia times were longer, waiting times were shorter, and the incidence of primary nonfunction was comparable. Among ETKAS recipients, HLA matching was more favorable in SA (mean 3.7 versus 2.5). In multivariate modeling, the incidence of graft loss in ETKAS recipients was reduced in RA compared with SA (subdistribution hazard ratio, 0.80; 95% confidence interval [0.70-0.91], P < 0.001), whereas other outcomes (mortality, death with functioning graft (DwFG)) were not significantly different. None of the 3 outcomes were significantly different when comparing RA with SA within the ESP program.
CONCLUSIONS
Facing increased waiting times and mortality on dialysis due to donor shortage, this study reveals encouragingly positive DDRT outcomes following RA. This supports the extension of RA to more patients and as an alternative tool to enable transplantation in patients in countries with prohibitively long waiting times or at risk of deterioration.

Identifiants

pubmed: 34608103
doi: 10.1097/TP.0000000000003964
pii: 00007890-202206000-00022
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1215-1226

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors declare no funding or conflicts of interest.

Références

Organ Procurement and Transplantation Network (OPTN). Policies, policy 8: allocation of kidneys. 2021. Available at https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf . Accessed January 12, 2020.
Eurotransplant Manual Version 8.2. Chapter 4: kidney (ETKAS and ESP). Eurotransplant Foundation; 2020. Available at https://my.eurotransplant.org/wp-content/uploads/2020/11/H4-Kidney-2020.3-November-2020.pdf . Accessed January 12, 2020.
Kidney Advisory Group on behalf of NHS Blood and Transplant (NHSBT) AP. Kidney transplantation: deceased donor organ allocation, POL186/10. 2019. Available at https://nhsbtdbe.blob.core.windows.net/umbraco-assets-corp/16915/kidney-allocation-policy-pol186.pdf . Accessed January 12, 2020.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730.
Eurotransplant Manual Version 8.2. Chapter 3–allocation general. Eurotransplant Foundation; 2020. Available at https://my.eurotransplant.org/wp-content/uploads/2020/09/H3-Allocation-v2020.2-September-2020.pdf . Accessed January 12, 2020.
Vinkers MT, Smits JM, Tieken IC, et al. Kidney donation and transplantation in Eurotransplant 2006-2007: minimizing discard rates by using a rescue allocation policy. Prog Transplant. 2009;19:365–370.
Farid S, Aldouri A, Fraser S, et al. Outcomes of kidney grafts refused by one or more centers and subsequently transplanted at a single United Kingdom center. Transplant Proc. 2009;41:1541–1546.
Assfalg V, Misselwitz S, Renders L, et al. Kidney transplantation after rescue allocation-meticulous selection yields the chance for excellent outcome. Nephrol Dial Transplant. 2021;36:551–560.
Metzger RA, Delmonico FL, Feng S, et al. Expanded criteria donors for kidney transplantation. Am J Transplant. 2003;3(suppl 4):114–125.
Querard AH, Le Borgne F, Dion A, et al. Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: toward increasing the pool of marginal donors. Am J Transplant. 2018;18:1151–1157.
Ko KJ, Kim YH, Kwon KH, et al. Kidney transplantation using expanded-criteria deceased donors: a comparison with ideal deceased donors and non-expanded-criteria deceased donors. Transplant Proc. 2018;50:3222–3227.
Merion RM, Ashby VB, Wolfe RA, et al. Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA. 2005;294:2726–2733.
Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002;74:1377–1381.
Assfalg V, Hüser N, van Meel M, et al. High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrol Dial Transplant. 2016;31:1515–1522.
Assfalg V, Selig K, Tolksdorf J, et al. Repeated kidney re-transplantation—the Eurotransplant experience: a retrospective multicenter outcome analysis. Transpl Int. 2020;33:617–631.
Hughes RA, Heron J, Sterne JAC, et al. Accounting for missing data in statistical analyses: multiple imputation is not always the answer. Int J Epidemiol. 2019;48:1294–1304.
Ranganathan P, Pramesh CS. Censoring in survival analysis: potential for bias. Perspect Clin Res. 2012;3:40.
Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer; 2000.
Scheike TH, Sun Y, Zhang M-J, et al. A semiparametric random effects model for multivariate competing risks data. Biometrika. 2010;97:133–145.
Scheike TH, Zhang M-J. Flexible competing risks regression modeling and goodness-of-fit. Lifetime Data Anal. 2008;14:464–483.
Scheike TH, Zhang M-J. Analyzing competing risk data using the R timereg package. J Stat Softw. 2011;38:i02.
Heinze G, Dunkler D. Five myths about variable selection. Transpl Int. 2017;30:6–10.
Yacoub R, Nadkarni GN, Cravedi P, et al. Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. Kidney Int. 2018;93:482–490.
Debout A, Foucher Y, Trébern-Launay K, et al. Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. Kidney Int. 2015;87:343–349.
Postalcioglu M, Kaze AD, Byun BC, et al. Association of cold ischemia time with acute renal transplant rejection. Transplantation. 2018;102:1188–1194.
Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant. 2001;15:89–94.
Opelz G, Döhler B. Association of HLA mismatch with death with a functioning graft after kidney transplantation: a collaborative transplant study report. Am J Transplant. 2012;12:3031–3038.
Therneau TM, Lumley T, Atkinson E, et al. A package for survival analysis in S. Version 2.38. 2015. Available at https://CRAN.R-project.org/package=survival . Accessed January 12, 2020.
Ozenne B, Sorensen AL, Scheike T, et al. riskRegression: predicting the risk of an event using cox regression models. R J. 2017;9:440–460.
Wahba R, Teschner S, Stippel DL. Results of kidney transplantation after rescue allocation. Transpl Int. 2011;24:e46–e47.
Wahba R, Suwelack B, Arns W, et al. Rescue allocation and recipient oriented extended allocation in kidney transplantation-influence of the EUROTRANSPLANT allocation system on recipient selection and graft survival for initially nonaccepted organs. Transpl Int. 2017;30:1226–1233.
Haugen CE, Chu NM, Ying H, et al. Frailty and access to kidney transplantation. Clin J Am Soc Nephrol. 2019;14:576–582.
McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty and early hospital readmission after kidney transplantation. Am J Transplant. 2013;13:2091–2095.
McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty as a novel predictor of mortality and hospitalization in individuals of all ages undergoing hemodialysis. J Am Geriatr Soc. 2013;61:896–901.
McAdams-DeMarco MA, Law A, King E, et al. Frailty and mortality in kidney transplant recipients. Am J Transplant. 2015;15:149–154.
Pelletier RP, Pesavento TE, Rajab A, et al. High mortality in diabetic recipients of high KDPI deceased donor kidneys. Clin Transplant. 2016;30:940–945.
Mehdorn A-S, Reuter S, Suwelack B, et al. Comparison of kidney allograft survival in the Eurotransplant senior program after changing the allocation criteria in 2010-A single center experience. PLoS One. 2020;15:e0235680.

Auteurs

Volker Assfalg (V)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Surgery, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Gregor Miller (G)

Department of Mathematics, Technical University of Munich, Garching, Germany.

Felix Stocker (F)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Surgery, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Marieke van Meel (M)

Eurotransplant International Foundation, Leiden, The Netherlands.

Tiny Groenevelt (T)

Eurotransplant International Foundation, Leiden, The Netherlands.

Ineke Tieken (I)

Eurotransplant International Foundation, Leiden, The Netherlands.

Donna Ankerst (D)

Department of Mathematics, Technical University of Munich, Garching, Germany.

Lutz Renders (L)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Nephrology, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Alexander Novotny (A)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Surgery, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Daniel Hartmann (D)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Surgery, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Alissa Jell (A)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Surgery, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Axel Rahmel (A)

Eurotransplant International Foundation, Leiden, The Netherlands.

Roger Wahba (R)

Department of General Visceral Cancer and Transplant Surgery, Transplant Center Cologne, University of Cologne Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.

Anja Mühlfeld (A)

Department of Nephrology, Universitätsklinikum Aachen, Aachen, Germany.

Antonia Bouts (A)

Department of Pediatric Nephrology, Emma Children's Hospital, Amsterdam UMC, Amsterdam, The Netherlands.

Dirk Ysebaert (D)

Department of Surgery, Antwerp University Hospital & University of Antwerp, Edegem, Antwerpen, Belgium.

Brigitta Globke (B)

Department of Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.

Daniel Jacobs-Tulleneers-Thevissen (D)

Department of Surgery, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.

László Piros (L)

Department of Transplantation and Surgery, School of Medicine, Semmelweis University, Budapest, Hungary.

Dirk Stippel (D)

Department of General Visceral Cancer and Transplant Surgery, Transplant Center Cologne, University of Cologne Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.

Katharina Heller (K)

Medizinische Klinik 4, Universitätsklinikum Erlangen-Nürnberg, Transplantation szentrum Erlangen-Nürnberg, Erlangen, Germany.

Ute Eisenberger (U)

Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.

Steven van Laecke (S)

Renal Department, University Hospital Gent, Gent, Belgium.

Rolf Weimer (R)

Department of Internal Medicine, Nephrology and Renal Transplantation, University Clinic of Giessen and Marburg (UKGM), Giessen, Germany.

Alexander R Rosenkranz (AR)

Universitätsklinik für Innere Medizin, Nephrologie, Medizinische Universität Graz, Graz, Austria.

Stefan Berger (S)

Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Lutz Fischer (L)

Department of Visceral Transplant Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Volker Kliem (V)

Division of Nephrology, Department of Internal Medicine, Transplantationszentrum Hannoversch Münden, Münden, Germany.

Florian Vondran (F)

Department for General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.

Urban Sester (U)

Department of Internal Medicine IV, Nephrology and Hypertension, Saarland University Medical Center and Saarland University Faculty of Medicine, Homburg, Germany.

Stefan Schneeberger (S)

Department of Visceral, Transplant and Thoracic Surgery, Medical University of Innsbruck, Innsbruck, Austria.

Ana Harth (A)

Medizinische Klinik I, Kliniken der Stadt Köln gGmbH, Lehrstuhl für Innere Medizin II, Nephrologie, Uniklinik Witten/Herdecke, Köln, Germany.

Dirk Kuypers (D)

Department of Nephrology, University Hospitals Leuven, Leuven, Belgium.

Reinhold Függer (R)

Department of Surgery, Ordensklinikum Elisabethinen Linz, Linz, Austria.

Miha Arnol (M)

Department of Nephrology and Renal Transplantation, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Maarten Christiaans (M)

Division of Nephrology, Department of Internal Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.

Julia Weinmann-Menke (J)

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Schwerpunkt Nephrologie und Nierentransplantation, Mainz, Germany.

Bernd Krüger (B)

Department of Nephrology, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany.

Luuk Hilbrands (L)

Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands.

Bernhard Banas (B)

Department of Nephrology, Universitätsklinikum Regensburg, Universitäres Transplantationszentrum, Regensburg, Germany.

Oliver Hakenberg (O)

Department of Urology, University Hospital Rostock, Rostock, Germany.

Robert Minnee (R)

Division of HPB and Transplant Surgery, Department of Surgery, Erasmus MC Transplant Institute, Rotterdam, The Netherlands.

Vedat Schwenger (V)

Department of Nephrology, Klinikum der Landeshauptstadt Stuttgart, Katharinenhospital, Stuttgart, Germany.

Nils Heyne (N)

Department of Internal Medicine IV, Section of Nephrology and Hypertension, Tübingen University Hospital, Tübingen, Germany.

Arjan van Zuilen (A)

Department of Nephrology, University Medical Center Utrecht, Utrecht, The Netherlands.

Roman Reindl-Schwaighofer (R)

Division of Nephrology and Dialysis, Department of Internal Medicine III, Medical University of Vienna, Wien, Austria.

Kai Lopau (K)

Division of Nephrology, Department of Internal Medicine 1, University hospital Wuerzburg, Würzburg, Germany.

Norbert Hüser (N)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Surgery, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Uwe Heemann (U)

TransplanTUM Munich Transplant Center, Interdisciplinary Transplant Center, Technical University of Munich, TUM School of Medicine, München, Germany.
Department of Nephrology, Technical University of Munich, TUM School of Medicine, Klinikum rechts der Isar, München, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH